2-溴-4’-(1-吡咯烷基)苯乙酮 | 216144-18-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-溴-4’-(1-吡咯烷基)苯乙酮
• 中文别名: 2-溴-4'-(1-吡咯烷基)苯乙酮；2-溴-1-(4-(吡咯啉-1-基)苯基)乙酮；α-溴-4-(1-吡咯烷)苯乙酮；ALPHA-溴-4-(1-吡咯烷基)乙酰苯酮
• 英文名称: α-bromo-4-(1-pyrrolidino)acetophenone
• 英文别名: 2-bromo-1-(4-(pyrrolidin-1-yl)phenyl)ethan-1-one；2-bromo-1-(4-(pyrrolidin-1-yl)phenyl)ethanone；2-bromo-1-(4-(1-pyrrolidinyl)phenyl)ethanone；2-bromo-1-(4-pyrrolidin-1-ylphenyl)ethanone
• CAS: 216144-18-2
• 化学式: C₁₂H₁₄BrNO
• 分子量: 268.153
• InChiKey: WLRIUCQUMKJOGT-UHFFFAOYSA-N

物化性质

• 熔点：
  120-122°C
• 沸点：
  386.6±22.0 °C(Predicted)
• 密度：
  1.421±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  避氧化物和碱。

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  8
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 危险品运输编号：
  UN 3261
• 储存条件：
  保存方法：应存放在密闭、阴凉、通风干燥的地方。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-1-(4-(pyrrolidin-1-yl)phenyl)ethanone
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H314: Causes severe skin burns and eye damage
H318: Causes serious eye damage
P260: Do not breathe dust/fume/gas/mist/vapours/spray
P303+P361+P353: IF ON SKIN (or hair): Remove/Take off immediately all contaminated clothing. Rinse skin with
water/shower
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P301+P330+P331: IF SWALLOWED: Rinse mouth. Do NOT induce vomiting
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-1-(4-(pyrrolidin-1-yl)phenyl)ethanone
CAS number: 216144-18-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H14BrNO
Molecular weight: 268.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN3261 Class: 8 Packing group: III
Proper shipping name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S. (2-Bromo-1-(4-(pyrrolidin-1-yl)phenyl)ethanone)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-4’-(1-吡咯烷基)苯乙酮 在 lithium hydroxide 、 sodium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.33h， 生成 2-[[2-Oxo-2-(4-pyrrolidin-1-ylphenyl)ethyl]-phenylmethoxycarbonylamino]acetic acid
  参考文献：
  名称：

  恶唑并[3,2-a]吡嗪-5-酮的高效，立体选择性合成：由3-氮杂-1,5-酮酸和氨基醇的双环缩合形成的新型双环内酰胺支架。

  摘要：

  [反应：见正文] 3-氮杂-1,5-酮酸和氨基醇的双环缩合反应提供了新颖的恶唑并[3,2-a]吡嗪-5-酮支架，该支架具有高产率的角，环连接取代基，且具有极好的环磷酰胺水平基于底物的非对映控制。丝氨酸衍生的支架的轻度氧化提供了一种新的受约束的二肽替代物。这些支架中所含的内环胺的脱保护作用允许通过N-官能化进一步多样化。

  DOI：

  10.1021/ol030065h
• 作为产物：
  描述：

  4’-(1-吡咯烷基)苯乙酮 在 N-溴代丁二酰亚胺(NBS) 、 对甲苯磺酸 作用下， 以 水 、 乙腈 为溶剂， 生成 2-溴-4’-(1-吡咯烷基)苯乙酮
  参考文献：
  名称：

  核独立化学位移 (NICS) 作为新抗真菌苯并呋喃酮设计的标准

  摘要：

  吴等人的断言。芳香性可能对分子设计有相当大的影响，促使我们使用核独立化学位移 (NICS) 作为芳香性标准来评估两个系列的 indol-4-one 的抗真菌活性。NICS 和抗真菌活性的线性回归分析表明，两个测试变量显着相关（p< 0.05); 当芳香性增加时，系列 I 的抗真菌活性降低，系列 II 的抗真菌活性增加。为了验证所得到方程的有效性，通过用氧取代 indol-4-ones 中的五元环的氮原子，设计了一组新的 44 benzofuran-4-ones。计算了苯并呋喃-4-酮的 NICS(0) 和 NICS(1)，并使用前面的方程来预测它们的生物活性。一组 10 苯并呋喃 4-ones 合成并在八种人类致病真菌中进行测试，显示了方程的有效性。对于光滑念珠菌、克柔念珠菌和吉列念珠菌与化合物15 -酵母菌的最低抑菌浓度 (MIC) 为 31.25 µg·mL –132，15 - 15和15

  DOI：

  10.3390/molecules26165078

文献信息

• Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis
  申请人：Cai Xiong Sui

  公开号：US20050014759A1

  公开（公告）日：2005-01-20

  The present invention is directed to substituted 1-benzoyl-3-cyano-pyrrolo[1,2-a]quinolines and analogs thereof, represented by the general Formula I: wherein R 1 —R 8 , L, Q, dash line and Ar are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及取代的1-苯甲酰基-3-氰基-吡咯并[1,2-a]喹啉及其类似物，由通用式I表示： 其中R1-R8，L，Q，虚线和Ar在此定义。本发明还涉及发现具有式I的化合物是caspase的激活剂和凋亡诱导剂。因此，本发明的caspase激活剂和凋亡诱导剂可用于诱导在各种临床病况中发生未受控制的异常细胞生长和扩散的细胞死亡。
• 2-Amino- and 2-hydroxymethylbenzimidazolium bromides as protein tyrosine phosphatase 1В (PTP1В) inhibitors and other targets associated with diabetes mellitus
  作者：A. A. Spasov、O. N. Zhukovskaya、D. A. Babkov、A. A. Brigadirova、V. A. Babkova、A. S. Morkovnik、R. A. Litvinov、E. V. Sokolova

  DOI：10.1007/s11172-020-2832-5

  日期：2020.4

  benzimidazolium bromides with a biphenyl-containing substituent at the imidazole nitrogen atom. In some cases, these bromides exhibit activity against targets associated with diabetes mellitus. These compounds are strong protein tyrosine phosphatase 1B (PTP1B) inhibitors, exhibit chelating and antiglycation activity, but have no significant AT 1 receptor antagonist activity. Hence, biphenyl-containing benzimidazolium

  合成了新的 2-氨基和 2-羟甲基苯并咪唑，并用于制备以前未知的 1,2,3-三和 1,2,3,5-四取代苯并咪唑溴化物，在咪唑氮原子处具有含联苯的取代基。在某些情况下，这些溴化物表现出针对与糖尿病相关的靶标的活性。这些化合物是强蛋白酪氨酸磷酸酶 1B (PTP1B) 抑制剂，具有螯合和抗糖化活性，但没有显着的 AT 1 受体拮抗剂活性。因此，含联苯的苯并咪唑鎓衍生物可被视为开发用于治疗 2 型糖尿病 (DM2) 和其他由高磷酸酶 PTP1B 活性介导的疾病的新药物的基础。
• Fe-Catalyzed Cycloisomerization of Aryl Allenyl Ketones: Access to 3-Arylidene-indan-1-ones
  作者：Johannes Teske、Bernd Plietker

  DOI：10.1021/acs.orglett.8b00612

  日期：2018.4.20

  A cycloisomerization of aryl allenyl ketones to 3-arylidene-indan-1-ones using a cationic Fe-complex as a catalyst is reported. The catalyst opens a synthetically interesting reaction pathway to this surprisingly underrepresented class of indanones that are not accessible using alternative catalytic systems.

  报道了使用阳离子铁络合物作为催化剂将芳基烯基酮环异构化成3-亚芳基-茚满-1-酮。催化剂为这种令人惊奇地代表性不足的茚满酮类打开了合成上令人感兴趣的反应途径，而使用替代的催化体系是无法达到的。
• Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase.
  申请人：Sireen AG

  公开号：EP1555264A1

  公开（公告）日：2005-07-20

  The present invention refers to novel substituted aromatic heteroaryl derivatives of formula (I). with the definitions of A, L1, L2, G, J, X and Y according to claim 1. These novel compounds are useful for the inhibition of protein kinases, particularly of the inhibition of Src family protein kinases. Methods for inhibiting kinases by contacting kinases with these novel compounds are disclosed. In another embodiment the present invention refers to pharmaceutical compositions containing these novel compounds and their use for the preparation of medicaments for treating diseases or disorders associated with unphysiological activity of kinases in the body, particularly for the treatment of cancer, immunosuppression, and osteoporosis.

  本发明涉及公式（I）的新型取代芳香杂环衍生物，其中A、L1、L2、G、J、X和Y的定义如权利要求1所述。这些新型化合物对蛋白激酶的抑制具有用处，特别是对Src家族蛋白激酶的抑制。公开了通过将这些新型化合物与激酶接触来抑制激酶的方法。在另一实施方式中，本发明涉及含有这些新型化合物的药物组合物，以及它们用于制备用于治疗体内激酶非生理活性相关疾病或紊乱的药物，特别是用于癌症、免疫抑制和骨质疏松症的治疗。
• Synthesis and structure–activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis
  作者：Emanuela Pesce、Marta Bellotti、Nara Liessi、Sara Guariento、Gianluca Damonte、Elena Cichero、Andrea Galatini、Annalisa Salis、Ambra Gianotti、Nicoletta Pedemonte、Olga Zegarra-Moran、Paola Fossa、Luis J.V. Galietta、Enrico Millo

  DOI：10.1016/j.ejmech.2015.05.030

  日期：2015.6

  targeted by small molecules called generically correctors and potentiators, respectively. Aminoarylthiazoles (AATs) represent an interesting class of compounds that includes molecules with dual activity, as correctors and potentiators. With the aim to improve the activity profile of AATs, we have now designed and synthesized a library of novel compounds in order to establish an initial SAR that may provide

  囊性纤维化跨膜电导调节剂 (CFTR) 是存在于上皮细胞膜中的氯离子通道。影响CFTR的突变基因导致囊性纤维化（CF），一种多器官严重疾病。最常见的 CF 突变 F508del 会损害 CFTR 蛋白的加工和活性（门控）。其他突变，如 G551D，只会导致门控缺陷。加工和门控缺陷可以分别被称为一般校正剂和增强剂的小分子作为目标。氨基芳基噻唑 (AAT) 代表了一类有趣的化合物，包括具有双重活性的分子，作为校正剂和增强剂。为了改善 AAT 的活性特征，我们现在设计并合成了一个新化合物库，以建立一个初始 SAR，该 SAR 可以提供有关对救援活动有益或有害的化学基团的指示。使用功能测定法在表达 CFBE41o 的 F508del-CFTR 中测试了新化合物作为校正剂和增强剂。双重活性化合物 AAT-如图 4a 所示，当与校正剂 VX-809 组合时，其特征在于提高的功效和显着的协同作用。此外，通过计算方法，已检测到核苷酸结合域